foxo4-dri human trials results Frontiers Figure 4 — FOXO4-DRI alleviates
Description
MHRA-measured Phase-3 Cav,ss 491/1470 ng/mL at 5/15 mg
Dose frequency should relate to the severity of the deficiency
Common side effects include mild soreness or redness at the injection site, which typically resolves quickly
Values are presented as the mean SD and as the minimum/median/maximum
What is FTPP peptide FTPP stands for Fat-Targeted Proapoptotic Peptide
However, gastrointestinal side effects (nausea, constipation, diarrhea) still occur, typically mild to moderate in severity
